Business Description
Protara Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US74365U1079
Share Class Description:
FRA:1KPA: Ordinary SharesTotal Employee Number:
51Description
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 51.84 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36.1 | |||||
3-Year EPS without NRI Growth Rate | 25.5 | |||||
3-Year FCF Growth Rate | 17.6 | |||||
3-Year Book Growth Rate | -26 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.22 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.09 | |||||
9-Day RSI | 53.99 | |||||
14-Day RSI | 52.33 | |||||
3-1 Month Momentum % | -0.31 | |||||
6-1 Month Momentum % | -27 | |||||
12-1 Month Momentum % | 24.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.97 | |||||
Quick Ratio | 10.97 | |||||
Cash Ratio | 10.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -68.2 | |||||
Shareholder Yield % | 0.51 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -42.92 | |||||
ROA % | -39.82 | |||||
ROIC % | -202.46 | |||||
3-Year ROIIC % | -113.13 | |||||
ROC (Joel Greenblatt) % | -1888.64 | |||||
ROCE % | -46.47 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.5 | |||||
Price-to-Tangible-Book | 1.56 | |||||
EV-to-EBIT | -1.08 | |||||
EV-to-Forward-EBIT | -0.89 | |||||
EV-to-EBITDA | -1.08 | |||||
EV-to-Forward-Revenue | 23.59 | |||||
EV-to-FCF | -1.3 | |||||
| Price-to-Net-Current-Asset-Value | 1.85 | |||||
| Price-to-Net-Cash | 1.9 | |||||
Earnings Yield (Greenblatt) % | -92.49 | |||||
FCF Yield % | -29.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Protara Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.161 | ||
| Beta | 1.1589 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 1.18 | ||
| Volatility % | 81.72 | ||
| 14-Day RSI | 52.33 | ||
| 14-Day ATR (€) | 0.098785 | ||
| 20-Day SMA (€) | 3.2163 | ||
| 12-1 Month Momentum % | 24.5 | ||
| 52-Week Range (€) | 2.48 - 6.5 | ||
| Shares Outstanding (Mil) | 59.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Protara Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Protara Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-03-10 | In 175 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-10 | In 175 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 55 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-15 14:00 | 3.36 (+9.80%) | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 3.38 (+0.00%) | ||
| General meeting for 2026 | 2026-06-12 12:00 | 3.10 (+0.00%) | ||
| Protara Therapeutics Lymphatic Malformations KOL Webinar | 2026-05-19 16:30 | 4.16 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 4.26 (+0.00%) | ||
| Annual report for 2025 | 2026-03-10 | 4.80 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 4.80 (+0.00%) |
Show
Entries
Protara Therapeutics Inc Frequently Asked Questions
What is Protara Therapeutics Inc(FRA:1KPA)'s stock price today?
The current price of FRA:1KPA is €3.31. The 52 week high of FRA:1KPA is €6.50 and 52 week low is €2.48.
When is next earnings date of Protara Therapeutics Inc(FRA:1KPA)?
The next earnings date of Protara Therapeutics Inc(FRA:1KPA) is 2026-11-10 Est..
Does Protara Therapeutics Inc(FRA:1KPA) pay dividends? If so, how much?
Protara Therapeutics Inc(FRA:1KPA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers